sb 216763 has been researched along with Bipolar Disorder in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Alam, MS; Hamid, H; Khan, I; Tantray, MA | 1 |
| Han, IO; Jung, EH; Kim, SM; Lee, JW; Lee, Y; Park, J | 1 |
| Dawson, LA; Kalinichev, M | 1 |
1 review(s) available for sb 216763 and Bipolar Disorder
| Article | Year |
|---|---|
Natural and synthetic bioactive inhibitors of glycogen synthase kinase.
Topics: Alzheimer Disease; Animals; Bipolar Disorder; Clinical Trials as Topic; Diabetes Mellitus; Drug Discovery; Glycogen Synthase Kinase 3; Humans; Models, Molecular; Neoplasms; Patents as Topic; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction | 2017 |
2 other study(ies) available for sb 216763 and Bipolar Disorder
| Article | Year |
|---|---|
Lithium chloride promotes lipid accumulation through increased reactive oxygen species generation.
Topics: AMP-Activated Protein Kinases; Animals; Antimanic Agents; Bipolar Disorder; Glycogen Synthase Kinase 3 beta; Hep G2 Cells; Humans; Indoles; Isoquinolines; Lipid Metabolism; Lithium Chloride; Liver; Maleimides; Mice; RAW 264.7 Cells; Reactive Oxygen Species; Sulfonamides; Weight Gain; Zebrafish | 2020 |
Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania.
Topics: Amphetamine; Animals; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Blood-Brain Barrier; Central Nervous System Stimulants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glycogen Synthase Kinase 3; Humans; Indoles; Male; Maleimides; Mice; Mice, Mutant Strains; Molecular Targeted Therapy; Motor Activity; Reproducibility of Results; Thiadiazoles; Thiazoles; Urea | 2011 |